CASI Pharmaceuticals, Inc. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

CASI Pharmaceuticals, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $28.54 million for the year ending 2024.

  • CASI Pharmaceuticals, Inc. showed a decrease of -15.8% in Revenue From Contract With Customer Excluding Assessed Tax from 2023 to 2024.
  • This data is from CASI Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
  • XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2020 to 2024), CASI Pharmaceuticals, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 90.2%.
  • Historical annual values: Fiscal year 2024: $28.54 million | Fiscal year 2023: $33.88 million | Fiscal year 2022: $38.05 million | Fiscal year 2021: $30.02 million | Fiscal year 2020: $15.00 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: